AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36435633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal vaccines
Number of subjects: 0
Study 36435928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural crest tumour treatment
Number of subjects: 6
Study 36435949 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for calculating Lp(a)-C from molar measurement of Lp(a) (Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL)
Number of subjects: 0
Study 36435949 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula for estimating Lp(a)-C as 30% of measured Lp(a) mass
Number of subjects: 0
Study 36435952 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher survivor perceived relationship quality
Number of subjects: 90
Study 36435952 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher spouse perceived relationship quality
Number of subjects: 90
Study 36436013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pancreas size measured at 20-22 weeks and 24-28 weeks
Number of subjects: 109
Study 36436013 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP)
Number of subjects: 109
Study 36436013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 109
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of endocrine therapy (ET)
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-persistence of endocrine therapy (ET)
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with non-initiation
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with non-persistence
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and symptom burden
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence associated with non-persistence
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making
Number of subjects: 693
Study 36436128 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in decision-making
Number of subjects: 693
Study 36436259 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (T1)
Number of subjects: 1256
Study 36436259 — intervention group
Group type: EXPERIMENTAL
Intervention: General anxiety (T1)
Number of subjects: 1256
Study 36436259 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cases/deaths (T0)
Number of subjects: 1256
Study 36436279 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood
Number of subjects: 97
Study 36436279 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in CSF
Number of subjects: 97
Study 36436279 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood at month 12
Number of subjects: 97
Study 36436279 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood at month 18
Number of subjects: 97
Study 36436279 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection for relapse detection
Number of subjects: 97
Study 36436320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine treatment for 14 days
Number of subjects: 14
Study 36436423 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET) with genomic testing using 70-gene and 80-gene signatures
Number of subjects: 67
Study 36436423 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 67
Study 36436542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-informed prognostic scoring system
Number of subjects: 13284
Study 36436542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-informed genomic scoring system
Number of subjects: 13284
Study 36436542 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in men vs women
Number of subjects: 13284
Study 36436542 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in prospective validation cohorts
Number of subjects: 13284
Study 36436542 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in Dusseldorf MDS registry
Number of subjects: 13284
Study 36436615 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD V15 Gy ≥10%
Number of subjects: 449
Study 36436615 — intervention group
Group type: COMPARATOR
Intervention: LAD V15 Gy <10%
Number of subjects: 449
Study 36436615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean heart dose ≥10 Gy
Number of subjects: 449
Study 36436615 — intervention group
Group type: COMPARATOR
Intervention: Mean heart dose <10 Gy
Number of subjects: 449
Study 36436704 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of CoronaVac (N = 134)
Number of subjects: 523
Study 36436704 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of BNT162b2 (N = 133)
Number of subjects: 523
Study 36436704 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of ChAdOx1 (N = 127)
Number of subjects: 523
Study 36436704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 129)
Number of subjects: 523
Study 36436827 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sAXL levels
Number of subjects: 1030
Study 36436827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of sAXL and NT-proBNP
Number of subjects: 1030
Study 36437124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative covert stroke
Number of subjects: 159
Study 36437124 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ischaemic brain injury
Number of subjects: 159
Study 36437124 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired imaging analysis
Number of subjects: 159
Study 36437124 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light levels
Number of subjects: 159
Study 36437219 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham score (risk score)
Number of subjects: 276
Study 36437418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (BBIBP-CorV), 2 doses on days 0 and 21
Number of subjects: 480
Study 36437469 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 490
Study 36437469 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 490
Study 36437469 — intervention group
Group type: COMPARATOR
Intervention: Support Vector Machine (SVM)
Number of subjects: 490
Study 36437469 — intervention group
Group type: COMPARATOR
Intervention: Elastic Net (EN)
Number of subjects: 490
Study 36437469 — intervention group
Group type: COMPARATOR
Intervention: L1 and L2 penalty models
Number of subjects: 490
Study 36437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsy, quantitative sensory testing, tilt-table testing, painDetect, Small Fibre Neuropathy Screening List, COMPASS-31 questionnaire
Number of subjects: 31
Study 36437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Number of subjects: 31
Study 36437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Number of subjects: 31
Study 36437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table testing
Number of subjects: 31
Study 36438334 — intervention group
Group type: EXPERIMENTAL
Intervention: Garden intervention with six standardized, raised, mulched garden beds and a Gardening Activity Guide for hands-on activities.
Number of subjects: 285
Study 36438334 — intervention group
Group type: EXPERIMENTAL
Intervention: Garden intervention
Number of subjects: 285
Study 36438334 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 285
Study 36438334 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 285
Study 36438439 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including support for local quality improvement teams, tailored education and resources, support from kidney transplant recipients and living kidney donors, and program-level performance reports.
Number of subjects: 10000
Study 36438439 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10000
Study 36438589 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide (TA) 4 mg/0.1 mL
Number of subjects: 39
Study 36438753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented PV (70 mL daily for 8 weeks)
Number of subjects: 80
Study 36438753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (70 mL daily for 8 weeks)
Number of subjects: 80
Study 36438959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 43
Study 36438959 — intervention group
Group type: COMPARATOR
Intervention: Dim Red Light (dRL)
Number of subjects: 43
Study 36438970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS
Number of subjects: 116
Study 36438970 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS
Number of subjects: 116
Study 36438970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active MDB
Number of subjects: 116
Study 36438970 — intervention group
Group type: COMPARATOR
Intervention: Sham MDB
Number of subjects: 116
Study 36438970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments
Number of subjects: 116
Study 36438970 — intervention group
Group type: COMPARATOR
Intervention: Sham treatments
Number of subjects: 116
Study 36438970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS and Active MDB
Number of subjects: 116
Study 36438970 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS and Sham MDB
Number of subjects: 116
Study 36439164 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR-2, CCL-5, IL-6 expression in lymphocytes and macrophages
Number of subjects: 27
Study 36439164 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CCR-2 with IL-6 and IL-10
Number of subjects: 27
Study 36439164 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic infection process characterization
Number of subjects: 27
Study 36439419 — intervention group
Group type: EXPERIMENTAL
Intervention: Supercritical extract of rosemary (SFRE)
Number of subjects: 0
Study 36439419 — intervention group
Group type: EXPERIMENTAL
Intervention: SFRE formulated with bioactive lipids
Number of subjects: 0
Study 36439865 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery to Facilitate Sensorimotor Re-Learning (MOTIFS) training intervention
Number of subjects: 12
Study 36439865 — intervention group
Group type: COMPARATOR
Intervention: Care-as-Usual (CaU) training
Number of subjects: 12
Study 36439999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 29
Study 36440011 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT-5a
Number of subjects: 64
Study 36440011 — intervention group
Group type: EXPERIMENTAL
Intervention: sFRP-5
Number of subjects: 64
Study 36440011 — intervention group
Group type: EXPERIMENTAL
Intervention: WIF-1
Number of subjects: 64
Study 36440011 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT-5a, WIF-1
Number of subjects: 64
Study 36440097 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg once daily)
Number of subjects: 77
Study 36440097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 36440464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 297
Study 36440464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 297
Study 36440464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 297
Study 36440464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 36440533 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (none, one or two doses)
Number of subjects: 2985
Study 36440533 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (fully vaccinated)
Number of subjects: 2985
Study 36440533 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination status and previous SARS-CoV-2 infection
Number of subjects: 2985
Study 36440533 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 80 years, presence of comorbidities, high care dependency
Number of subjects: 2985
Study 36441083 — intervention group
Group type: EXPERIMENTAL
Intervention: Human macrophage cell therapy
Number of subjects: 0
Study 36441083 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cell analytics
Number of subjects: 0
Study 36441346 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA vascular parameters (RPC-VD%, SCP-VD%, DCP-VD%)
Number of subjects: 152
Study 36441346 — intervention group
Group type: EXPERIMENTAL
Intervention: PhNR amplitude
Number of subjects: 152
Study 36441346 — intervention group
Group type: EXPERIMENTAL
Intervention: PhNR implicit time
Number of subjects: 152
Study 36441346 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC-VD and PhNR amplitude
Number of subjects: 152
Study 36441346 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP-VD, RNFL, and GCC thickness
Number of subjects: 152
Study 36441357 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06462700 (equine anti-thymocyte immunoglobulin) administered intravenously at 40 mg/kg/day for 4 days
Number of subjects: 3
Study 36441436 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily)
Number of subjects: 13
Study 36441446 — intervention group
Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzer (WSA) under-mattress device for 7 nights
Number of subjects: 35
Study 36441446 — intervention group
Group type: COMPARATOR
Intervention: Peripheral arterial tonometry (PAT) home sleep apnea test (HSAT)
Number of subjects: 35
Study 36441446 — intervention group
Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzer (WSA) under-mattress device
Number of subjects: 35
Study 36441551 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based lifestyle program plus supervised exercise (exercise group)
Number of subjects: 116
Study 36441551 — intervention group
Group type: COMPARATOR
Intervention: Family-based lifestyle program (control group)
Number of subjects: 116
Study 36441574 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exergame intervention for 4 months
Number of subjects: 100
Study 36441574 — intervention group
Group type: COMPARATOR
Intervention: Standard home exercise protocol
Number of subjects: 100
Study 36441715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention exercise
Number of subjects: 126
Study 36441718 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiovascular risk (CVR) as calculated using FRESCO and REGICOR tables
Number of subjects: 962
Study 36441718 — intervention group
Group type: COMPARATOR
Intervention: Low cardiovascular risk (CVR) as calculated using FRESCO and REGICOR tables
Number of subjects: 962
Study 36441736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 32
Study 36441736 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (INP)
Number of subjects: 32
Study 36441736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine (OLA)
Number of subjects: 32
Study 36441736 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (PL)
Number of subjects: 32
Study 36441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab (P+T)
Number of subjects: 134
Study 36441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Paclitaxel (P+T+paclitaxel)
Number of subjects: 134
Study 36441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene signatures related to immune response (IR)
Number of subjects: 134
Study 36441798 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCAness signature
Number of subjects: 134
Study 36441798 — intervention group
Group type: EXPERIMENTAL
Intervention: sTILs (baseline/week 3/change)
Number of subjects: 134
Study 36441994 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND (8-week mindfulness-based intervention during pregnancy)
Number of subjects: 162
Study 36441994 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 162
Study 36442353 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 therapy
Number of subjects: 172
Study 36442665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear Potentiated Startle (FPS)
Number of subjects: 306
Study 36442665 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Conductance Response (SCR)
Number of subjects: 306
Study 36442665 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based cognitive behavioral therapy
Number of subjects: 306
Study 36442803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative optic nerve sheath diameter (ONSD) measured 5 minutes after reperfusion
Number of subjects: 100
Study 36442815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Psychological Flexibility Inventory (MPFI)
Number of subjects: 404
Study 36442892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous OP-724 infusion at a dosage of 280 mg/m²
Number of subjects: 7
Study 36442892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous OP-724 infusion at a dosage of 380 mg/m²
Number of subjects: 7
Study 36442911 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell recruiting bispecific antibodies (T-biAbs) targeting Siglec-6 and CD3, including JML-1 and RC-1.
Number of subjects: 0
Study 36442911 — intervention group
Group type: EXPERIMENTAL
Intervention: JML-1 T-biAb
Number of subjects: 0
Study 36442911 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-1 T-biAb
Number of subjects: 0
Study 36442911 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-2 mAb
Number of subjects: 0
Study 36443171 — intervention group
Group type: EXPERIMENTAL
Intervention: CUD-002 vaccine consisting of dendritic cells loaded with mRNA encoding personalized tumor neoantigens
Number of subjects: 0
Study 36443208 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-ancestry GWAS meta-analysis
Number of subjects: 2018
Study 36443208 — intervention group
Group type: COMPARATOR
Intervention: Known adult lipid loci
Number of subjects: 2018
Study 36443400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 264
Study 36443400 — intervention group
Group type: COMPARATOR
Intervention: No gestational diabetes mellitus (Control)
Number of subjects: 264
Study 36443540 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 217
Study 36443540 — intervention group
Group type: COMPARATOR
Intervention: Non-chemotherapy
Number of subjects: 217
Study 36443540 — intervention group
Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 217
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system readiness measures (staffing levels, glove stockouts, distance to reference laboratory)
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Staffing levels
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove stockouts
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to reference laboratory
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Catchment area size
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple NGOs supporting PMTCT services
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility type, stockout of prophylactic antiretrovirals, presence of quality improvement programs, mothers' support groups
Number of subjects: 3427
Study 36443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive HIV diagnosis
Number of subjects: 3427
Study 36443816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil extracellular traps (NET)
Number of subjects: 162
Study 36443816 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-activated neutrophil culture supernatant
Number of subjects: 162
Study 36443816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil elastase (NE) and myeloperoxidase (MPO)
Number of subjects: 162
Study 36443816 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-associated markers and fragmentation size profiles
Number of subjects: 162
Study 36443816 — intervention group
Group type: EXPERIMENTAL
Intervention: NET
Number of subjects: 162
Study 36443816 — intervention group
Group type: COMPARATOR
Intervention: NE KO mice
Number of subjects: 162
Study 36443836 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined exercise programme (2 sessions/week: 30-min HIIT + 15-min resistance training)
Number of subjects: 180
Study 36443836 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 180
Study 36443836 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined exercise programme
Number of subjects: 180
Study 36444224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention initiated during chemotherapy (group A)
Number of subjects: 266
Study 36444224 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention initiated after chemotherapy (group B)
Number of subjects: 266
Study 36444227 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VCd (daratumumab, bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0
Study 36444227 — intervention group
Group type: COMPARATOR
Intervention: VCd (bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0
Study 36444227 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VCd
Number of subjects: 0
Study 36444227 — intervention group
Group type: COMPARATOR
Intervention: VCd
Number of subjects: 0
Study 36444315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800
Study 36444315 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800
Study 36444319 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Coagulation-Inflammation (SCI) index
Number of subjects: 1967
Study 36444319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including SCI index
Number of subjects: 1967
Study 36444331 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 95
Study 36444374 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF (budesonide/glycopyrronium/formoterol fumarate dihydrate) 320/14.4/10 µg
Number of subjects: 0